StoneMor Partners L.P. Obtains New York Stock Exchange Listing Extension
Sep 19, 2017 20:05 pm UTC| Business
TREVOSE, Pa., Sept. 19, 2017 -- StoneMor Partners L.P. (NYSE:STON) (“StoneMor” or the “Partnership”) announced today that it has received an extension for continued listing and trading on the New York Stock Exchange...
Novavax to Present at the Ladenburg Thalmann 2017 Healthcare Conference
Sep 19, 2017 20:05 pm UTC| Business
GAITHERSBURG, Md., Sept. 19, 2017 -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will present at the Ladenburg Thalmann 2017 Healthcare Conference. Presentation details are as follows: Date: Tuesday,...
ÉLÉPHANT VERT and Marrone Bio Innovations Sign Distribution Agreement in North Africa
Sep 19, 2017 20:05 pm UTC| Business
DAVIS, Calif., Sept. 19, 2017 -- Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI), based in Davis, California, is a leading provider of bio-based pest management and plant health products for agriculture, turf,...
Zafgen to Present at the 2017 Ladenburg Thalmann Healthcare Conference
Sep 19, 2017 20:05 pm UTC| Business
BOSTON, Sept. 19, 2017 -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and...
Relievant Medsystems Names Kevin Hykes Chief Executive Officer
Sep 19, 2017 20:03 pm UTC| Business
SUNNYVALE, Calif., Sept. 19, 2017 -- Relievant Medsystems, a privately held medical device company that has developed the Intracept® Procedure, a minimally invasive and clinically proven approach for the treatment of...
SMG Indium Resources Acquires Texas Oilfield Services Company
Sep 19, 2017 20:02 pm UTC| Business
NEW YORK and HOUSTON, Sept. 19, 2017 -- SMG Indium Resources Ltd. (the "Company" or "SMG") (OTCPK:SMGI), today announced that it has acquired 100% of the membership interests of MG Cleaners LLC, an oilfield services...
Gemphire Announces Plans to Advance Gemcabene into Phase 3 Clinical Development
Sep 19, 2017 20:01 pm UTC| Business
New analysis of data shows clinically meaningful reductions in LDL-C and hsCRP across multiple trials and confirms support to advance gemcabene into Phase 3 End of Phase 2 meetings planned for early 2018 ROYAL-1 study...